Zhang Lanjun: Targeted inhibitors with low possibility of drug resistance will be the first choice for clinical treatment of ALK non-small cell lung cancer-China News Service Shanghai


2022-09-23: [Chinese Article Link] The AALK clinical treatment for non-small cell lung cancer will be the preferred target of low resistance to drugs. 23 September 2022 1900 Source: China-New Online Sea In a lung cancer known as the “first cancer killer” in our country, the AlK subtype of non-small cell lung cancer in China and New


Note: This is a machine translated version of the Chinese news media article. A mature and nuanced reading is suggested.


What China Reads


Zhang Lanjun: Targeted inhibitors with low possibility of drug resistance will be the first choice for clinical treatment of ALK non-small cell lung cancer-China News Service Shanghai


2022-09-23: [Article Link] The AALK clinical treatment for non-small cell lung cancer will be the preferred target of low resistance to drugs. 23 September 2022 1900 Source: China-New Online Sea In a lung cancer known as the “first cancer killer” in our country, the AlK subtype of non-small cell lung cancer in China and New

Note: This is a translated version of the Chinese news media article. A mature and nuanced reading is suggested.